![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Gilead gains Forty Seven’s investigational immuno-oncology therapy in multiple clinical studies, supporting its strategic focus in oncology as well as innovative pipeline.
Lead Product(s): Magrolimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $4,900.0 million Upfront Cash: $4,900.0 million
Deal Type: Acquisition March 02, 2020